Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04690413 · ClinicalTrials.gov registry record · NA

NOWDx Test for the Detection of Antibodies to COVID-19

A NA study of COVID-19 and SARS-CoV-2, sponsored by NOWDiagnostics.

Completed
Registry status
NA
Development phase
129
Enrollment target
3
Study locations

NCT04690413 is a NA study of COVID-19 and SARS-CoV-2 that has completed, run by NOWDiagnostics. The registered enrollment target is 129 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04690413, a NA study of COVID-19 and SARS-CoV-2, has completed, sponsored by NOWDiagnostics.

COMPLETED
Registry status
NA
Development phase
129 participants
Enrollment target
3
Study locations

Study Summary

This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (venous and fingerstick).

Interventions

  • DEVICE NOWDx COVID-19 Test

Study Locations (3)

Arizona

  • Del Sol Research Management, LLC - Tucson

Florida

  • Comprehensive Clinical Research, LLC - West Palm Beach

Tennessee

  • Clinical Research Solutions, LLC - Jackson

Trial Details

FieldValue
Enrollment Target 129 participants
Start Date 2020-09-01
Est. Completion 2020-12-31
Phase NA

Sponsor

NOWDiagnostics

4 total trials

What the Registry Record Tells You About NCT04690413

The ClinicalTrials.gov registry entry for NCT04690413 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is NOWDiagnostics, which has 4 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which NOWDx COVID-19 Test is the first listed.

NCT04690413 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Florida, Tennessee.

Frequently Asked Questions

What is clinical trial NCT04690413 about?

NCT04690413 is a clinical study titled "NOWDx Test for the Detection of Antibodies to COVID-19". This study is designed to compare the performance of the NOWDx COVID-19 Test to an emergency use authorized PCR test result. The intent is to show the rapid test device is comparable to a currently marketed device. The NOWDx COVID-19 Test is an in vitro lateral flow immunoassay intended for qualitat...

What is the current status of trial NCT04690413?

This trial is currently completed. It is a NA study. The enrollment target is 129 participants. The study started on 2020-09-01. Estimated completion is 2020-12-31.

What conditions does trial NCT04690413 study?

This clinical trial studies the following conditions: COVID-19, SARS-CoV-2, Coronavirus.

What interventions are being tested in trial NCT04690413?

The interventions under investigation include: NOWDx COVID-19 Test (DEVICE).

Who is sponsoring clinical trial NCT04690413?

This trial is sponsored by NOWDiagnostics, which has 4 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04690413 being conducted?

This trial has 3 study locations across Arizona, Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.